Free trial

Ask AI to review this stock

Copy the prompt to get recent events, historical reactions, and a short research brief.

Tell your AI:

Help me set up FinLab and analyze HUM Humana Inc.. Please read: https://finlab.finance/en/setup?stock=HUM

No install, open FinLab Studio

HUM

Humana Inc. Healthcare As of 2026-07-31 Updated daily after market close

quality needs a look, premium valuation.

2 active signals

Top-quintile 6-month momentum Filed revenue acceleration

This page refreshes daily after the close. Add Humana Inc. to your watchlist to track signal changes on your next visit.

Is Humana Inc. a buy? Fundamentals and valuation first

Quality is weaker than peers. Operating margin is only around the 38th percentile. TTM ROE is about 6.1%.
Valuation is expensive. TTM P/E is in the 87th percentile, above most peers.
Recent volatility is moderate. 60-day annualized volatility is near the 48th percentile. Average 20-day dollar volume is about $578.8M.
Signals are active now. Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.

Historical evidence

Signals active now

Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.

Top-quintile 6-month momentum

Active · now 95.74468085106383%

The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.

20 historical occurrences (since 2017-01-09)

120 days after: historical avg +7.44%

20-day +3.25%

60-day +7.1%

120-day +7.44%

20-day

60-day

120-day

Win

55%

73.7%

68.4%

Sample

Median

+1.91%

+6.87%

+15.05%

Excess

+2.85%

+2.93%

-0.02%

Beat mkt rate

65%

68.4%

57.9%

Over 19 occurrences, 120-day forward avg gained 7.44%, lagged the market by 0.02 pts; win rate 68.4%.

Filed revenue acceleration

Active · now 14.084249388834369%

TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.

13 historical occurrences (since 2019-07-31)

120 days after: historical avg +5.22%

20-day +0.37%

60-day +10.19%

120-day +5.22%

20-day

60-day

120-day

Win

53.8%

61.5%

72.7%

Sample

Median

+0.3%

+5.64%

+9.64%

Excess

+0.44%

+7.24%

-2.34%

Beat mkt rate

46.2%

53.8%

45.5%

Over 11 occurrences, 120-day forward avg gained 5.22%, lagged the market by 2.34 pts; win rate 72.7%.

Valuation regime and forward returns

Daily TTM P/E is converted into an expanding own-history percentile, then grouped into five valuation regimes. Forward returns use adjusted prices over the next 240 trading days.

0-20 +9.5%

20-40 -3.2%

40-60 -2.1%

60-80 -8.1%

80-100 -19.5% Now

PE percentile band	Sample days	240-day avg return	Median	Win rate	Avg excess (vs index)
0-20	285	+9.5%	+5.7%	73.7%	-13.2%
20-40	380	-3.2%	+0.1%	50.3%	-19%
40-60	230	-2.1%	+0.6%	51.7%	-16.2%
60-80	295	-8.1%	-7.2%	37.3%	-16.7%
80-100 You are here	192	-19.5%	-20.1%	9.4%	-33.6%

Quarterly EPS is aligned by SEC filing date before it is forward-filled to daily prices. The expanding percentile uses only information available up to each day.

Current TTM P/E is about 38.92, placing it in the 96.6 own-history percentile, inside the 80-100 bucket.

Valuation × momentum analogs

Each historical day is grouped by own-history P/E tercile and 60-day momentum direction, then tested for the next 120-trading-day adjusted return.

Valuation

Momentum

Cheap (own-history bottom third)

Middle

Expensive (own-history top third)

60-day momentum up

-1.2%

Win rate 57.4% Excess -15.2%

230d

-3.7%

Win rate 56.5% Excess -7.5%

333d

Now

-11.6%

Win rate 14.8% Excess -18%

237d

60-day momentum down

+7.4%

Win rate 70.5% Excess -4.2%

325d

+4.4%

Win rate 70.9% Excess +3.5%

148d

-0.7%

Win rate 36.2% Excess -7.7%

229d

Currently in “Expensive (own-history top third) × 60-day momentum up”: across 237 historical days, 120-day forward avg declined 11.6%, win rate 14.8%, lagged the market by 18%.

Days = trading days in this bucket; returns use adjusted prices, ex-costs. 60-day momentum: direction of this stock's price over the past 60 trading days.

Market-wide momentum baseline

Across 97,878 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.26%, a 58.3% positive-return rate, and +2.90 percentage points of average excess return versus the S&P 500.

Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).

Signals not active now

Inactive signals still show the stock-specific historical forward-return distribution for context.

52-week adjusted-price high

Pending

Adjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.

23 times historically; 60-day forward avg +2.68%, win rate 66.7%, beating the market by +0.6 pts on average.

EPS surprise beat

Pending

Reported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.

21 times historically; 60-day forward avg -1.08%, win rate 57.1%, beating the market by -5.81 pts on average.

Method and limits

Returns use us_price:adj_close, adjusted for splits and dividends where available.
Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
Overlapping event windows are descriptive distributions, not independent samples.

This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.